Maksim Mamonkin, PhD

Dr. Mamonkin received a PhD and postdoctoral training from Baylor College of Medicine, where he is leading a team focused on preclinical, manufacturing, and translational development of highly innovative engineered T-cell therapies for hematologic malignancies and alloimmunity.

Dr. Mamonkin’s research has yielded significant outcomes, including the initiation of 4 phase 1 clinical trials in leukemia and lymphoma, both in collaboration with academic institutions and sponsored by the industry. Additionally, his work has resulted in the licensing of multiple patents to biotech companies. With his expertise and contributions to the field, Dr. Mamonkin plays a vital role in advancing the understanding and application of engineered T-cell therapies, bringing new hope for patients with hematologic malignancies and alloimmune disorders.